Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

S&P Biotech SPDR (NY: XBI )

74.19 +0.47 (+0.64%)
Official Closing Price Updated: 8:00 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 8,180,392
Open 73.43
Bid (Size) 74.29 (5)
Ask (Size) 74.34 (3)
Prev. Close 73.72
Today's Range 72.44 - 74.51
52wk Range 61.78 - 97.15
Shares Outstanding 882,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Want Diversified Upside in Biotechnology? Check out LABU
Watch the Direxion Daily S&P 500 Biotech Bull 3X Shares (NYSEARCA: LABU) if you want a speculative play in the biotechnology industry with amplified volatility. 
Via MarketBeat
Topics ETFs Stocks
Exposures US Equities
US Judge Weighs Nationwide Ban On Abortion Pills
U.S. District Judge Matthew Kacsmaryk questioned President Joe Biden's administration lawyers on whether the federal regulatory approval of the abortion pill mifepristone was proper. The judge is... 
Via Benzinga

Performance

YTD
-9.00%
-9.00%
1 Month
-8.94%
-8.94%
3 Month
-5.54%
-5.54%
6 Month
-1.16%
-1.16%
1 Year
-17.30%
-17.30%

More News

Read More
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
Via InvestorPlace
Biotech Stocks And The SVB Collapse — Here's What We Know
Via Investor's Business Daily
Silicon Valley Bank Meltdown Hits Healthcare Sector As Well
Via Benzinga
Small Cap Biotechs Slammed By SVB Collapse
Via Talk Markets
6 Stock Market Thoughts For The Week Of March 13
Via Talk Markets
Hefty Listing Price Of New Drugs For Cancer, Rare Diseases Put Pressure On Annual Hike For Older Drugs
Via Benzinga
FDA Seeks 10% Increase In Biden's FY 2024 Budget, Proposes Enhancing Regulatory Authorities
Via Benzinga
Healthcare Is Lagging But Biotech Offers Good Potential For Value And Trading
Via Talk Markets
FDA Takes Action To Restrict Unlawful Import Of Animal Tranquilizer 'Tranq' Or ''Zombie Drug'
Via Benzinga
When Small Cap Biotechs Lose Momentum: Are You An Investor Or A Trader?
Via Talk Markets
Stryker, DaVita And These 2 ETFs: CNBC's 'Final Trades'
Via Benzinga
Sector Shift Stalls Healthcare Stocks But Biotech Shows Gains In January
Via Talk Markets
2 ETFs That Can Set You Up for Life
Via The Motley Fool
Healthcare Sector Is Lagging As We Enter 2022 Earnings Season
Via Talk Markets
The Fed Should Stop Right Now
Via Talk Markets
J.P.Morgan Healthcare Conference JPM23: Biotech Rally Favors Smaller Caps
Via Talk Markets
Nice Gains During JPM23 Week: Benign CPI Report Brings Hope For A “Soft Landing”
Via Talk Markets
3 Unstoppable ETFs to Stock Up On in 2023
Via The Motley Fool
ETFs To Buy For 2023 After S&P 500's Worst Year Since 2008
Via Talk Markets
CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks
Via Investor's Business Daily
5 Top Stocks for January
Via The Motley Fool
The Year In Review And Ahead
Via Talk Markets
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.